当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2013年
11期
71
,共1页
保留肾单位手术%根治性肾切除术%肾癌%肾功能
保留腎單位手術%根治性腎切除術%腎癌%腎功能
보류신단위수술%근치성신절제술%신암%신공능
Nephron-sparing surgery%Radical nephrectomy%Kidney cancer%Renal function
目的探讨分析保留肾单位手术与根治性肾切除手术治疗肾癌的疗效差异,以供临床参考.方法选择2010年2月~2012年2月连州市人民医院收治的72例肾癌患者为研究对象,将所有患者随机分为I组和I 组,符合方差齐性与可比性,其中I组给予保留肾单位手术,I 组给予根治性肾切除手术,对比观察两组患者的治疗效果.结果两组患者手术时间、术中出血量和手术后引流量比较,P>0.05,差异无统计学意义;保留肾单位组患者手术后肾功能变化小,与根治组比较,P<0.05,差异有统计学意义.结论对肾癌的临床治疗选择保留肾单位手术的效果更好,对患者的肾功能影响小,损伤小,值得临床推广应用.
目的探討分析保留腎單位手術與根治性腎切除手術治療腎癌的療效差異,以供臨床參攷.方法選擇2010年2月~2012年2月連州市人民醫院收治的72例腎癌患者為研究對象,將所有患者隨機分為I組和I 組,符閤方差齊性與可比性,其中I組給予保留腎單位手術,I 組給予根治性腎切除手術,對比觀察兩組患者的治療效果.結果兩組患者手術時間、術中齣血量和手術後引流量比較,P>0.05,差異無統計學意義;保留腎單位組患者手術後腎功能變化小,與根治組比較,P<0.05,差異有統計學意義.結論對腎癌的臨床治療選擇保留腎單位手術的效果更好,對患者的腎功能影響小,損傷小,值得臨床推廣應用.
목적탐토분석보류신단위수술여근치성신절제수술치료신암적료효차이,이공림상삼고.방법선택2010년2월~2012년2월련주시인민의원수치적72례신암환자위연구대상,장소유환자수궤분위I조화I 조,부합방차제성여가비성,기중I조급여보류신단위수술,I 조급여근치성신절제수술,대비관찰량조환자적치료효과.결과량조환자수술시간、술중출혈량화수술후인류량비교,P>0.05,차이무통계학의의;보류신단위조환자수술후신공능변화소,여근치조비교,P<0.05,차이유통계학의의.결론대신암적림상치료선택보류신단위수술적효과경호,대환자적신공능영향소,손상소,치득림상추엄응용.
Objective To investigate the analysis of nephron-sparing surgery and radical nephrectomy difference in the efficacy of the surgical treatment of renal cell reserved for clinical reference. Methods From February 2010 to February 2012 72 cases of kidney cancer patients admitted for the study, which group I give nephron-sparing surgery, II group were treated with radical nephrectomy surgery. The two groups of patients randomized to meet the homogeneity of variance and comparability. In contrast to observe the therapeutic effect of the two groups of patients. Results The patients operative time, blood loss and post-operative drainage volume differences are not significant, P> 0.05, the difference was not statistically significant; small changes in renal function after renal unit patients surgery reserved, free survival ratescompared with the radical group were significantly different, P<0.05, the difference was statistically significant. Conclusion The effect of nephron-sparing surgery for the clinical treatment of kidney cancer is higher, the impact on renal function in patients with small, small damage, more worthy of application.